CHIESI FARMACEUTICI S.P.A.

Chapters cover methodology, executive summary, market variables, segmentation by disease, molecule, biological target, mechanism, and region, and competitive landscape.

Protalix BioTherapeutics (PLX) is a clinical-stage biopharmaceutical company developing therapeutic proteins using its ProCellEx® system. Key products include Taliglucerase Alfa for Gaucher disease and Elfabrio® for Fabry disease, with strategic partnerships with Pfizer and Chiesi Farmaceutici S.p.A. The company's robust pipeline includes PRX-115 for severe gout and PRX-119 for NETs-related diseases. Protalix maintains strong financial resilience and operational stability despite regional security challenges.

Protalix BioTherapeutics to present phase I PRX-115 trial data at ACR Convergence 2024, showcasing prolonged plasma urate-lowering effect for uncontrolled gout treatment.

Pharmas focus on Phase II companies, with 40% of M&A deals completed in under six weeks. Capital markets remain uncertain, leading to more private companies with advanced assets. Deals are more competitive, with mid-caps and European players becoming active acquirers.